Table 1.
Baseline Characteristics
| Total (N = 11) | |
|---|---|
| Age (years), mean ± SD | 65.5 ± 9.7 |
| Gender (male), n (%) | 9 (82) |
| Race (Caucasian), n (%) | 8 (73) |
| Body mass index, mean ± SD | 27.8 ± 5.6 |
| Ischemic etiology, n (%) | 7 (64) |
| Destination therapy, n (%) | 9 (82) |
| LVAD duration before ramp test (days), median (IQR) | 859 (246–1,310) |
| CRT-D support duration (days), median (IQR) | 1,219 (939–1,633) |
| LVAD type, n (%) | |
| HeartMate II | 8 (73) |
| HVAD | 3 (27) |
| CRT-D type, n (%) | |
| Boston scientific | 3 (27) |
| Medtronics | 6 (55) |
| St. Jude | 2 (18) |
| Hypertension | 5 (45) |
| Diabetes mellitus | 4 (36) |
| History of stroke | 2 (18) |
| Atrial fibrillation | 4 (36) |
| History of ventricular arrhythmia | 3 (27) |
CRT-D, cardiac resynchronization therapy defibrillator; IQR, interquartile range; LVAD, left ventricular assist device; SD, standard deviation.